既往难治药物再治疗多发性骨髓瘤
本回顾性研究纳入本机构315例复发/难治多发性骨髓瘤(RRMM)患者,描述以既往难治药物再治疗的结局:总缓解率56.2%,中位无进展生存期(PFS)11个月;初始用药时间>28.4个月者再治疗PFS更优(16.9 vs 8.1个月,P<.001),初始用药与再治疗间隔>46.1个月者PFS更优(28.2 vs 8.9个月,P=.016)。
要点
- 315例RRMM以既往难治药物再治疗,总缓解率56.2%,中位PFS 11个月。
- 初始用药时间>28.4个月者再治疗中位PFS 16.9 vs 8.1个月(P<.001)。
- 初始用药与再治疗间隔>46.1个月者中位PFS 28.2 vs 8.9个月(P=.016)。
核心结论
- 以既往难治药物再治疗是RRMM可行的治疗选择,对初始药物敏感及初始用药与再治疗间隔较长者获益最大。
研究设计与样本
- 本机构315例复发/难治多发性骨髓瘤(RRMM)患者的回顾性研究,描述以既往难治药物再治疗的结局。
主要发现
- 再治疗总缓解率56.2%,中位无进展生存期(PFS)11个月。
- 初始用药时间>28.4个月者再治疗中位PFS 16.9 vs 8.1个月(P<.001)。
- 初始用药与再治疗间隔>46.1个月者再治疗中位PFS 28.2 vs 8.9个月(P=.016)。
临床怎么用
- 作者认为,以既往难治药物再治疗是RRMM可行的治疗选择,对初始药物敏感及初始用药与再治疗间隔较长者获益最大。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
As patients with relapsed/refractory multiple myeloma (RRMM) continue to live longer, they might get exposed to most available drugs and drug classes during the disease course. For such late line RRMM or among patients without access to novel therapies, retreatment with a drug that the disease had previously been refractory to might be one option. In this retrospective study, we describe 315 patients with RRMM at our institution who were retreated with a drug that the disease had been previously refractory to. We found an overall response rate of 56.2% and a median progression-free survival (PFS) of 11 months with retreatment. Patients with a longer time on initial therapy with the index drug (>28.4 months) had a superior PFS with retreatment (median PFS, 16.9 vs 8.1 months; P < .001). Similarly, patients with a longer time gap between the initial line of therapy with index drug and retreatment with index drug (>46.1 months) had better PFS with retreatment (28.2 vs 8.9 months; P = .016). In conclusion, retreatment with a previously refractory drug is a viable therapeutic option for RRMM, with the most significant benefit derived in disease demonstrating sensitivity to initial drug exposure and among those with a longer gap between initial drug exposure and retreatment.
引用
- Goel U, Charalampous C, Kapoor P, et al. Retreatment of multiple myeloma with previously refractory drugs. Blood Adv. 2024. PMID: 39536293. doi:10.1182/bloodadvances.2024014723
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。